Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

• Sponsor: Yih-Ing Hser (Other)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT06023459
• Collaborator: National Institute on Drug Abuse (NIDA) (NIH), National Institutes of Health (NIH) (NIH), The Emmes Company, LLC (Industry), University of California, Los Angeles (Other), RAND (Other), Cornell University (Other), Oregon Health and Science University (Other), University of Illinois at Chicago (Other), University of Washington (Other), West Virginia University (Other)
• Enrollment: 144
• Locations: 6
• Arms: 2
• Anticipated Duration (Months): 12
• Patients Per Site: 24
• Patients Per Site Per Month: 2

Study Details

Study Description

Brief Summary

This pilot trial will explore the feasibility, acceptability, and effectiveness of the most recently approved formulation of injectable extended-release buprenorphine (XR-BUP) for treatment of opioid use disorder (OUD) in rural settings. We will randomize 144 eligible individuals with moderate to severe OUD in a 2:1 ratio to one of two medication conditions: (1) XR-BUP (128mg target), administered every 4 weeks or (2) SL-BUP (16mg-24 mg/day target).Participants will receive study medication treatment for the 14 week-intervention period, including an initial ~2-week period of induction/stabilization. The study will use a mixed-methods approach (participant assessments, study medication records, qualitative interviews) for assessing feasibility and acceptability, and results will include patient outcome data on the comparative effectiveness of XR-BUP versus SL-BUP for patients with OUD in rural settings.

Condition or Disease	Intervention/Treatment	Phase
Opioid-Related Disorders; Substance-Related Disorders; Narcotic-Related Disorders	Drug: Injectable extended-release buprenorphine; Drug: Sublingual buprenorphine-naloxone	Phase 3

Detailed Description

This 24-month randomized controlled open-label pilot study will be conducted in approximately 6 clinics in rural settings. The study objectives are to describe the feasibility of implementing the study in rural settings, document the acceptability of the XR-BUP condition, and assess the comparative effectiveness of XR-BUP compared with SL-BUP. Participants will be randomized within each clinic to XR-BUP or SL-BUP in a ratio of 2:1 (overall approximately 96 in the XR-BUP condition, 48 in the SL-BUP condition). They will receive study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization. The XR-BUP condition will use Brixadi®/CAM2038 injectable, extended-release buprenorphine. The measure for the main comparative effectiveness outcome is number of urine drug screen (UDS) results negative for opioids at scheduled assessments during Week 2 through Week 14 of the trial. Missing or positive UDS for any non-prescribed opioid is considered UDS positive.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 144 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: A 24-month randomized controlled open-label pilot study will be conducted in approximately 6 clinics in rural settings. Participants will be randomized within each clinic to XR-BUP or SL-BUP in a ratio of 2:1 (overall approximately 96 in the XR-BUP condition, 48 in the SL-BUP condition). They will receive study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization.A 24-month randomized controlled open-label pilot study will be conducted in approximately 6 clinics in rural settings. Participants will be randomized within each clinic to XR-BUP or SL-BUP in a ratio of 2:1 (overall approximately 96 in the XR-BUP condition, 48 in the SL-BUP condition). They will receive study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Randomized Controlled Pilot Trial of Extended-released Buprenorphine vs. Sublingual Buprenorphine-naloxone in Rural Settings
• Anticipated Study Start Date: Jan 1, 2024
• Anticipated Primary Completion Date: Nov 30, 2024
• Anticipated Study Completion Date: Dec 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Injectable extended-release buprenorphine (XR-BUP) Participants will be randomly assigned to XR-BUP, with approximately 96 in the XR-BUP condition. The XR-BUP condition will use Brixadi/CAM2038 injectable, extended-release buprenorphine (Braeburn Pharmaceuticals, Inc.). After titrating to a stable dosage in approximately two weeks using weekly injection dosages as clinically indicated to relieve cravings and withdrawal symptoms, the target monthly dosage (128mg) of XR-BUP will be administered by injection at approximately Day 14 and approximately four weeks later in Week 6, with a third injection in Week 10. Dosage adjustments will be made as indicated for tolerability.	Drug: Injectable extended-release buprenorphine; Participants randomized to the XR-BUP condition will receive XR-BUP study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization.; Other Names: XR-BUP (Brixadi)
Active Comparator: Sublingual buprenorphine-naloxone (SL-BUP) Participants will be randomly assigned to SL-BUP with approximately 48 in the SL-BUP condition. The SL-BUP condition will use sublingual buprenorphine-naloxone, with a target maintenance daily dose range of 16-24mg as recommended for clinical practice. Titration to maintenance dosage will be attempted within the first two weeks of the SL-BUP condition. During the initial stabilization weeks, SL-BUP will be flexibly dosed as clinically indicated to relieve cravings and withdrawal symptoms, after which dosage adjustments will be based on clinical decisions by the site clinicians. The maintenance dosage of SL-BUP will be dispensed on a schedule similar to the XR-BUP injections (i.e., at approximately Day 14, Week 6, and Week 10).	Drug: Sublingual buprenorphine-naloxone; Participants randomized to the SL-BUP condition will receive SL-BUP study medication for approximately 14 weeks following randomization, including an initial ~2-week period of induction/stabilization.; Other Names: SL-BUP

Outcome Measures

Primary Outcome Measures

1. Comparative effectiveness [Week 2 through Week 14 of the trial]

   Number or percentage of urine drug screen (UDS) results negative for opioids

Secondary Outcome Measures

1. Feasibility of study implementation [through study completion, an average of 1 year]

   Overall recruitment, study completion, study dropout during the 14-week intervention period, and qualitative feedback from clinic personnel and patients.

2. Acceptability of XR-BUP [through study completion, an average of 1 year]

   Initial patient medication preference prior to randomization, percentage of participants randomized to the XR-BUP condition who receive the first monthly injection, percentage of XR-BUP participants who receive at least the first two monthly injections, and qualitative feedback from clinic personnel and patients.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Be ≥18 years of age

2. Meet DSM-5 criteria for moderate to severe OUD or be on buprenorphine medication for OUD

3. Be interested in receiving buprenorphine treatment for OUD

4. Be willing to be randomized to either SL-BUP or XR-BUP

5. Be willing to comply with all study procedures

6. Be in good general health, as determined by the study Medical Clinician based on medical/psychiatric histories and physical exam, to permit treatment in an outpatient setting

7. If female of childbearing potential, be willing to practice an effective method of birth control for the duration of participation in the study intervention and agree to study-administered pregnancy testing during their participation in the study

8. Be able to speak English sufficiently to understand the study procedures

9. Be willing and able to provide written informed consent to participate in the study

Exclusion Criteria:

1. Have evidence of a serious psychiatric disorder as assessed by the study Medical Clinician that would make participation difficult or unsafe (e.g., active psychosis, severe depression, or mania)

2. Have suicidal or homicidal ideation or behavior that requires immediate attention

3. Have a medical condition or serious medical illness that, in the opinion of the study Medical Clinician, would make study participation medically unsafe

4. Have been in treatment with naltrexone within 28 days of consent

5. Have been in methadone maintenance treatment within 28 days of consent

6. Be taking medication or require any medication that, in the judgment of the study Medical Clinician, could interact adversely with study medication

7. Have known allergy or sensitivity to SL-BUP or XR-BUP formulations or their components

8. Be currently incarcerated or have pending legal action that could preclude participation in study activities

9. Have other situation that might prevent the participant from remaining in the area for the duration of the study (e.g., planned move)

10. Have a current pattern of alcohol, benzodiazepine, or other sedative hypnotic use, as determined by the study Medical Clinician, that would require a different level of care and preclude safe participation in the study

11. Be currently pregnant or breastfeeding or planning on conception

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Southern Humboldt Community Healthcare District - Jerold Phelps Community Hospital	Garberville	California	United States	95542
2	Gibson Area Hospital and Health Services - Gibson Recovery Optimizing Wellness	Gibson City	Illinois	United States	60936
3	Oregon Health & Science University Primary Care Clinic, Scappoose	Scappoose	Oregon	United States	97056
4	Harbor Regional Health - HarborCrest Behavioral Health	Aberdeen	Washington	United States	98550
5	Providence Northeast Washington Medical Group	Colville	Washington	United States	99114
6	New Beginnings Recovery Clinic & Behavioral Health Center	New Martinsville	West Virginia	United States	26155

Sponsors and Collaborators

• Yih-Ing Hser
• National Institute on Drug Abuse (NIDA)
• National Institutes of Health (NIH)
• The Emmes Company, LLC
• University of California, Los Angeles
• RAND
• Cornell University
• Oregon Health and Science University
• University of Illinois at Chicago
• University of Washington
• West Virginia University

Investigators

• Principal Investigator: Yih-Ing Hser, PhD, University of California, Los Angeles
• Principal Investigator: Larissa Mooney, MD, University of California, Los Angeles

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Yih-Ing Hser, Distinguished Research Professor, Department of Psychiatry and Behavioral Sciences, Geffen School of Medicine, University of California, Los Angeles
• ClinicalTrials.gov Identifier: NCT06023459
• Other Study ID Numbers: CTN-0102-XR; UG1DA049435
• First Posted: Sep 5, 2023
• Last Update Posted: Sep 5, 2023
• Last Verified: Aug 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by Yih-Ing Hser, Distinguished Research Professor, Department of Psychiatry and Behavioral Sciences, Geffen School of Medicine, University of California, Los Angeles: Opioid Use Disorder; Opioid Medication Assisted Treatment; Buprenorphine; Comparative Effectiveness Research
• Additional relevant MeSH terms: Substance-Related Disorders; Opioid-Related Disorders; Narcotic-Related Disorders; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Naloxone

Study Results

No Results Posted as of Sep 5, 2023